Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years

Autor: Michelle A. Neller, George R. Ambalathingal, Nada Hamad, Joe Sasadeusz, Rebecca Pearson, Chien-Li Holmes-Liew, Deepak Singhal, Matthew Tunbridge, Wei Yang Ng, Kirsty Sharplin, Andrew Moore, David Deambrosis, Trisha Soosay-Raj, Peter McNaughton, Morag Whyte, Chris Fraser, Andrew Grigg, David Kliman, Ashish Bajel, Katherine Cummins, Mark Dowling, Zhi Han Yeoh, Simon J. Harrison, Amit Khot, Sarah Tan, Izanne Roos, Ray Mun Koo, Sara Dohrmann, David Ritchie, Brynn Wainstein, Karen McCleary, Adam Nelson, Bradley Gardiner, Shafqat Inam, Xavier Badoux, Kris Ma, Claudia Toro, Diane Hanna, David Hughes, Rachel Conyers, Theresa Cole, Shiqi Stacie Wang, Lynette Chee, Jacqueline Fleming, Ashley Irish, Duncan Purtill, Julian Cooney, Peter Shaw, Siok-Keen Tey, Stewart Hunt, Elango Subramonia Pillai, George John, Michelle Ng, Shanti Ramachandran, Peter Hopkins, Daniel Chambers, Scott Campbell, Ross Francis, Nicole Isbel, Paula Marlton, Hilary Reddiex, Katherine K. Matthews, Meggie Voogt, Archana Panikkar, Leone Beagley, Sweera Rehan, Shannon Best, Jyothy Raju, Laetitia Le Texier, Pauline Crooks, Matthew Solomon, Lea Lekieffre, Sriganesh Srihari, Corey Smith, Rajiv Khanna

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)

Abstract Adoptive T-cell immunotherapy holds great promise for the treatment of viral complications in immunocompromised patients resistant to standard anti-viral strategies. We present a retrospective analysis of 78 patients from 19 hospitals across

Externí odkaz: https://doaj.org/article/8c099c749c664bdd91639b09344ded19

SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants.

Autor: Archana Panikkar, Katie E Lineburg, Jyothy Raju, Keng Yih Chew, George R Ambalathingal, Sweera Rehan, Srividhya Swaminathan, Pauline Crooks, Laetitia Le Texier, Leone Beagley, Shannon Best, Matthew Solomon, Katherine K Matthews, Sriganesh Srihari, Michelle A Neller, Kirsty R Short, Rajiv Khanna, Corey Smith

Publikováno v: PLoS Pathogens, Vol 18, Iss 2, p e1010339 (2022)

Adoptive T-cell immunotherapy has provided promising results in the treatment of viral complications in humans, particularly in the context of immunocompromised patients who have exhausted all other clinical options. The capacity to expand T cells fr

Externí odkaz: https://doaj.org/article/c3b87232ebed482692dd6783b41f36ec

Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis

Autor: Michael P. Pender, Peter A. Csurhes, Corey Smith, Nanette L. Douglas, Michelle A. Neller, Katherine K. Matthews, Leone Beagley, Sweera Rehan, Pauline Crooks, Tracey J. Hopkins, Stefan Blum, Kerryn A. Green, Zara A. Ioannides, Andrew Swayne, Blake T. Aftab, Kaye D. Hooper, Scott R. Burrows, Kate M. Thompson, Alan Coulthard, Rajiv Khanna

Publikováno v: JCI Insight, Vol 5, Iss 20 (2020)

Externí odkaz: https://doaj.org/article/5220d02d3d4a4acaa623d7dda4d52f6c

Impact of pre‐therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV‐specific T‐cell therapy

Autor: David G Walker, Reshma Shakya, Beth Morrison, Michelle A Neller, Katherine K Matthews, John Nicholls, Corey Smith, Rajiv Khanna

Publikováno v: Clinical & Translational Immunology, Vol 8, Iss 11, Pp n/a-n/a (2019)

Abstract Objectives Clinical response to antibody‐based immunotherapies targeting checkpoint inhibitors is critically dependent on the tumor immune microenvironment (TIME). However, the precise impact of the TIME on adoptive cellular immunotherapy

Externí odkaz: https://doaj.org/article/1e2763ab58544f1e80a5945763e33a21

A Comparison of the Safety of Therapeutically Equivalent Doses of Isradipine and Diltiazem for Treatment of Essential Hypertension: An Alternative Viewpoint

Autor: Bruce P. Hamilton, Mahendr S. Kochar, Alan P. Abrams, Gerald H. Stein, E. Paul MacCarthy, Jonathan L. Isaacsohn, Katherine P. Matthews, Nicolaos E. Madias, Jennifer H. Hamilton, Henry R. Black, Mary Ellen Gibbons, Andrew J. Lewin

Publikováno v: American Journal of Hypertension. 5:141-146

We compared the safety of a new dihydropyridine calcium entry blocker, isradipine, with an equipotent dose of diltiazem in 174 mild hypertensives (diastolic blood pressure [DBP] 95 to 105 mm Hg). After appropriate washout and placebo periods, patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0249e0508c777ebaac3b48d3257979cc
https://doi.org/10.1093/ajh/5.3.141